Merck has been forced to delay marketing plans for its combination
cholesterol drug MK-0524B following problems in formulating its
top-selling statin Zocor (simvastatin) with a new promising
compound under development, MK-524A.
In the face of generic competition, Abbott has asked Irish
biotechnology firm Elan to use its NanoCrystal technology to
develop an "all in one" oral dose formulation combining two
cholesterol drugs, AstraZeneca's Crestor...
The battle to gain control of the lucrative cholesterol-lowering
drug market intensified after Merck and Schering-Plough joined
forces to win Food and Drug Administration (FDA) approval for their
new entrant, Vytorin.
The global generics industry is growing at such a rate that it can
now support billion dollar companies, with activities crossing into
active pharmaceutical ingredient (API) production and R&D. This
shift in the sector - from...